Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)

Thrombosis Research

Volumn 124, Issue 5, 2009, Pages

  Lussana, Federico ^a   Dentali, Francesco ^b   Abbate, Rosanna ^c   d'Aloja, Ernesto ^d   D'Angelo, Armando ^e   De Stefano, Valerio ^f   Faioni, Elena M ^a   Grandone, Elvira ^g   Legnani, Cristina ^h   Martinelli, Ida ⁱ   Simioni, Paolo ^j   Tormene, Daniela ^j  

^a Azienda Ospedaliera San Paolo Dipartimento di Medicina   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^j UNIVERSITY OF PADOVA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; DALTEPARIN; ENOXAPARIN; FOLIC ACID; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDICATION; FAMILY HISTORY; FEMALE; FETUS DEATH; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK POPULATION; HUMAN; HYPERHOMOCYSTEINEMIA; INTRAUTERINE GROWTH RETARDATION; MATERNAL MORBIDITY; MATERNAL MORTALITY; MEDICAL SOCIETY; OSTEOPOROSIS; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; RECURRENT ABORTION; RISK BENEFIT ANALYSIS; SCREENING TEST; SOLUTIO PLACENTAE; TERATOGENICITY; THROMBOCYTE COUNT; THROMBOGENESIS; THROMBOPHILIA; THROMBOSIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

EID: 70349866121     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.06.031     Document Type: Article

References (71)

1. Iorio A., Ageno W., Cosmi B., Imberti D., Lussana F., Siragusa S., et al. Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res 124 (2009) e1-e5
2. Scottish Intercollegiate Guidelines Network, SIGN 50: A guideline developers' handbook, SIGN Publication No. 50. February 2001, last updated May 2004. Available from: http://www.sign.ac.uk.
3. National Institute for Clinical Excellence, Guideline Development Methods: Information for National Collaborating Centres and Guideline Developers, London: National Institute for Clinical Excellence, February 2004, updated 2005. Available from: www.nice.org.
4. Pomp E.R., Lenselink A.M., Rosendaal F.R., and Doggen C.J. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 6 (2008) 632-637
5. Greer I.A. Thrombosis in pregnancy: maternal and fetal issues. Lancet 353 (1999) 1258-1265
6. Heit J.A., Kobbervig C.E., James A.H., Petterson T.M., Bailey K.R., and Melton III L.J. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: A 30-year population-based study. Ann Intern Med 143 (2005) 697-706
7. McColl M.D., Ramsay J.E., Tait R.C., Walker I.D., McCall F., Conkie J.A., et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 78 (1997) 1183-1188
8. Gerhardt A., Scharf R.E., Beckmann M.W., Struve S., Bender H.G., Pillny M., et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. New Engl J Med 342 (2000) 374-380
9. Middeldorp S., Libourel E.J., Hamulyak K., Van der Meer J., and Buller H.R. The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden. Br J Haematol 113 (2001) 553-555
10. Martinelli I., Legnani C., Bucciarelli P., Grandone E., De Stefano V., and Mannucci P.M. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost 86 (2001) 800-803
11. Martinelli I., De Stefano V., Taioli E., Paciaroni K., Rossi E., and Mannucci P.M. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 87 (2002) 791-795
12. Rey E., Kahn S.R., David M., and Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 9361 (2003) 901-908
13. Wu O., Robertson L., Twaddle S., Lowe G.D., Clark P., Greaves M., et al. Screening for thrombophilia in high-risk situations: Systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess (Winchester, England) 10 (2006) 1-110
14. Robertson L., Wu O., Langhorne P., Twaddle S., Clark P., Lowe G.D., et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 132 (2006) 171-196
15. Kovalevsky G., Gracia C.R., Berlin J.A., Sammel M.D., and Barnhart K.T. Evaluation of the Association between Hereditary Thrombophilias and Recurrent Pregnancy Loss: A Meta-analysis. Arch Intern Med 164 (2004) 558-563
16. Kosmas I.P., Tatsioni A., and Ioannidis J.P. Association of C677T polymorphism in the methylenetetrahydrofolate reductase gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. J Hypertens 22 (2004) 1655-1662
17. Alfirevic Z., Roberts D., Martlew V., Alfirevic Z., Roberts D., and Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol 101 (2002) 6-14
18. Biron-Andreani C., Schved J.F., and Daures J.P. Factor V Leiden mutation and pregnancy-related venous thromboembolism: What is the exact risk? results from a meta-analysis. Thromb Haemost 96 (2006) 638-646
19. Dudding T.E., Attia J., Dudding T.E., and Attia J. The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis. Thromb Haemost 91 (2004) 700-711
20. Howley H.E., Walker M., Rodger M.A., Howley H.E.A., Walker M., and Rodger M.A. A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. Am J Obstet Gynecol 192 (2005) 694-708
21. Kujovich J.L., and Kujovich J.L. Thrombophilia and pregnancy complications. Am J Obstet Gynecol 191 (2004) 412-424
22. Opatrny L., David M., Kahn S.R., Shrier I., and Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a meta-analysis. J Rheumatol 33 (2006) 2214-2221
23. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2006) 295-306
24. Lindqvist P.G., Svensson P.J., Marsal K., Grennert L., Luterkor M., and Dahlback B. Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost 81 (1999) 532-537
25. Lindqvist P.G., Svensson P., and Dahlback B. Activated protein C resistance - In the absence of factor V Leiden - And pregnancy. J Thromb Haemost 4 (2006) 361-366
26. McColl M.D., Ramsay J.E., Tait R.C., Walker I.D., McCall F., Conkie J.A., et al. Superficial vein thrombosis: Incidence in association with pregnancy and prevalence of thrombophilic defects. Thromb Haemost 79 (1998) 741-742
27. Bank I., Libourel E.J., Middeldorp S., Van Pampus E.C., Koopman M.M., Hamulyák K., et al. Prothrombin 20210A mutation: A mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Intern Med 164 (2004) 1932-1937
28. Friederich P.W., Sanson B.J., Simioni P., Zanardi S., Huisman M.V., Kindt I., et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 125 (1996) 955-960
29. Dizon-Townson D., Miller C., Sibai B., Spong C.Y., Thom E., Wendel Jr. G., et al. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet Gynecol 106 (2005) 517-524
30. Volzke H., Grimm R., Robinson D.M., Robinson C., Kohlmann T., Schuster G., et al. Factor V Leiden and the risk of stillbirth in a German population. Thromb Haemost 90 (2003) 429-433
31. Murphy R.P., Donoghue C., Nallen R.J., D'Mello M., Regan C., Whitehead A.S., et al. Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Vasc Biol 20 (2000) 266-270
32. Dizon-Townson D.S., Nelson L.M., Jang H., Varner M.W., and Ward K. The incidence of the factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis. Am J Obstet Gynecol 176 (1997) 883-886
33. Middeldorp S., Henkens C.M., Koopman M.M., van Pampus E.C., Hamulyàk K., van der Meer J., et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 128 (1998) 15-20
34. Clark P., Twaddle S., Walker I.D., Scott L., and Greer I.A. Cost-effectiveness of screening for the factor V Leiden mutation in pregnant women. Lancet 359 (2002) 1919-1920
35. Grandone E., Colaizzo D., Brancaccio V., Ciampa A., Di Minno G., and Margaglione M. Impact of prothrombotic mutations and family history on the occurrence of intra-uterine fetal deaths. Haematologica 87 (2002) 1118-1119
36. Couturaud F., Kearon C., Leroyer C., Mercier B., Abgrall J.F., Le Gal G., et al. Incidence of venous thromboembolism in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. Thromb Haemost 96 (2006) 744-749
37. Pabinger I., Schneider B., Pabinger I., and Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol 16 (1996) 742-748
38. Simioni P., Sanson B.-J., Prandoni P., Tormene D., Friederich P.W., Girolami B., et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 81 (1999) 198-202
39. Tormene D., Simioni P., Prandoni P., Luni S., Zerbinati P., Sartor D., et al. Factor V Leiden mutation and the risk of venous thromboembolism in pregnant women. Haematologica 86 (2001) 1305-1309
40. Tormene D., De Stefano V., Grandone E., Za T., Perlati M., Rossi E., et al. The G20210A prothrombin variant and the risk of venous thromboembolism or fetal loss in pregnant women: a family study. J Thromb Haemost 5 (2007) 2193-2196
41. Martinelli I., Battaglioli T., De Stefano V., Tormene D., Valdrè L., Grandone E., et al. The risk of first venous thromboembolism during pregnancy and puerperium in double heterozygotes for factor V Leiden and prothrombin G20210A. J Thromb Haemost 6 (2008) 494-498
42. Tormene D., Simioni P., Prandoni P., Luni S., Innella B., Sabbion P., et al. The risk of fetal loss in family members of probands with factor V Leiden mutation. Thromb Haemost 82 (1999) 1237-1239
43. Meinardi J.R., Middeldorp S., de Kam P.J., Koopman M.M., van Pampus E.C., Hamulyàk K., et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med 130 (1999) 736-739
44. Brouwer J.L., Veeger N.J., Kluin-Nelemans H.C., and Van Der M.J. The pathogenesis of venous thromboembolism: evidence for multiple interrelated causes. Ann Intern Med 145 (2006) 807-815
45. Brill-Edwards P., Ginsberg J.S., Gent M., Hirsh J., Burrows R., Kearon C., et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. New Engl J Med 343 (2000) 1439-1444
46. Pabinger I., Grafenhofer H., Kaider A., Kyrle P.A., Quehenberger P., Mannhalter C., et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost 3 (2005) 949-954
47. De Stefano V., Martinelli I., Rossi E., Battaglioli T., Za T., Mannucci P.M., et al. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol 135 (2006) 386-391
48. Simioni P., Tormene D., Prandoni P., and Girolami A. Pregnancy-related recurrent events in thrombophilic women with previous venous thromboembolism. Thromb Haemost 86 (2001) 929
49. Lissalde-Lavigne G., Fabbro-Peray P., Cochery-Nouvellon E., Mercier E., Ripart-Neveu S., Bladucchi J.P., et al. Factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: The matched case-control 'NOHA first' study. J Thromb Haemost 3 (2005) 2178-2184
50. Gris J.C., Mercier E., Quere I., Lavigne-Lissalde G., Cochery-Nouvellon E., Hoffet M., et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 103 (2004) 3695-3699
51. Brenner B., Hoffman R., Carp H., Dulitsky M., and Younis J. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost 3 (2005) 227-229
52. Empson M., Lassere M., Craig J., and Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2 (2005) CD002859
53. Bates S.M., Greer I.A., Hirsh J., and Ginsberg J.S. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 627S-644S
54. Greer I.A., and Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 106 (2005) 401-407
55. Sanson B.J., Lensing A.W., Prins M.H., Ginsberg J.S., Barkagan Z.S., Lavenne-Pardonge E., et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 81 (1999) 668-672
56. Gates S., Brocklehurst P., Davis L.J., Gates S., Brocklehurst P., and Davis L.J. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev 2 (2002) CD001689
57. Pettila V., Kaaja R., Leinonen P., Ekblad U., Kataja M., and Ikkala E. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thromb Res 96 (1999) 275-282
58. Dahlman T.C. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 168 (1993) 1265-1270
59. Lindqvist P., Dahlback B., and Marsal K. Thrombotic risk during pregnancy: A population study. Obstet Gynecol 94 (1999) 595-599
60. De Stefano V., Leone G., Mastrangelo S., Tripodi A., Rodeghiero F., Castaman G., et al. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 71 (1994) 799-800
61. Royal C.O.G. Thromboprophylaxis during pregnancy, labour and after vaginal delivery 6013. Guideline N37 (2004). http://www.rcog.org.uk www.rcog.org.uk
62. Howell R., Fidler J., Letsky E., and de Swiet M. The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. Br J Obstet Gynaecol 90 (1983) 1124-1128
63. Gates S., Brocklehurst P., Ayers S., Bowler U., and Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low-molecular-weight heparin. Am J Obstet Gynecol 191 (2004) 1296-1303
64. Tengborn L., Bergqvist D., Matzsch T., Bergqvist A., and Hedner U. Recurrent thromboembolism in pregnancy and puerperium. Is there a need for thromboprophylaxis?. Am J Obstet Gynecol 160 (1989) 90-94
65. Nelson-Piercy C., Letsky E.A., de S.M., Nelson-Piercy C., Letsky E.A., and de Swiet M. Low- molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 176 (1997) 1062-1068
66. Ellison J., Walker I.D., Greer I.A., Ellison J., Walker I.D., and Greer I.A. Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy. BJOG 107 (2000) 1116-1121
67. Hunt B.J., Doughty H.A., Majumdar G., Copplestone A., Kerslake S., Buchanan N., et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 77 (1997) 39-43
68. Lepercq J., Conard J., Borel-Derlon A., Darmon J.Y., Boudignat O., Francoual C., et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG 108 (2001) 1134-1140
69. Deruelle P., Denervaud M., Hachulla E., Ducloy-Bouthors A.S., Valat A.S., Puech F., et al. Use of low-molecular-weight heparin from the first trimester of pregnancy: A retrospective study of 111 consecutive pregnancies. Eur J Obstet Gynecol Reprod Biol 127 (2006) 73-78
70. Rowan J.A., McLintock C., Taylor R.S., and North R.A. Prophylactic and therapeutic enoxaparin during pregnancy: indications, outcomes and monitoring. Aust N Z J Obstet Gynaecol 43 (2003) 123-128
71. Blomback M., Bremme K., Hellgren M., Siegbahn A., and Lindberg H. Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy - A longitudinal safety study. Blood Coagul Fibrinolysis 9 (1998) 1-9